Monopar Therapeutics Inc. (MNPR)
| Previous close | 2.6900 |
| Open | 2.7500 |
| Bid | 2.5900 x 800 |
| Ask | 2.7900 x 1400 |
| Day's range | 2.7500 - 2.8000 |
| 52-week range | 1.3910 - 4.8800 |
| Volume | |
| Avg. volume | 23,077 |
| Market cap | 36.048M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7020 |
| Earnings date | 10 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.67 |
- GlobeNewswire
Monopar to Present at the 35th Annual Roth Conference
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Presentation Details: Date: March 13, 2023Time: 12:30-1:00 pm Pacific Time Location: The R
- GlobeNewswire
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr. Based on promising recently generated preclinical imaging results with MNPR-101-Zr showing high uptake across multiple tumor types, the companies also committed t
- GlobeNewswire
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS): Monopar has opened enrollment for the fifth dose level c
